Wed, Aug 20, 2014, 11:13 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

  • Johnnydoe1998 Johnnydoe1998 Dec 2, 1998 9:12 PM Flag

    Stop The Hype Onyx will go back up to se

    No matter what you guys say about Onyx. This
    stock is an excellent buy! This stock will go up about
    40% in the next few months and we might even see a
    big spike on announcement of Phase three clinical
    trials with ONYX-015. The results are great, the
    scientists back it up and the clinic has definitely proved
    its case. Forget the Journal Of Virology study. They
    didnt prove a thing! Optimal MOI's for the drug were
    surely decided before Phase 1. Anyways, the treatment
    has been working, molecular biology being correct or
    not. Isnt Zoloft one of the most prescribed anti
    depressants in the US?? Well, not much is known about its
    mechanism of action and its effect outside Serotonin
    Reuptake. There were groups and are groups still against
    the prescribing of such drugs to people who need
    them. The fact is, It has treated millions of people
    with anxiety disorders, depression etc...... Well, I
    am not saying ONYX-015 will be the CURE for all
    cancers, but it surely seems better than all the other
    remedies out there right now and has great potential.
    Believe in this company because I do believe in their
    studies!!!
    Another fact is that this company is
    expanding their basic and clinical research to different
    areas. Look at the new Rb target. If the entire business
    world was not busy watching the aol-Netscape merger
    they would have noticed the importance of the
    announcement. Well they have not as of yet but I'm sure News
    will catch on. You know what, I'm most likely buying
    more stocks.
    ----Just an opinion from a fellow
    stockholder

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I know you-all have seen it but I couldn't wait.
      New release,
      No Toxicity! We all knew this...I
      believe, but its good to see it in print from latest
      expansion in O-15 trials.
      Good Luck!
      darrel

    • Onyxmole, that sounds very interesting. Are they
      targeting cancer with the inhibitor? Which cancers would
      they go after? Do they pre-screen based on activation
      state of MAP kinase, or Ras? Any further info would be
      much appreciated.

    • To be sure... the exact mechanism for Raf1
      activation is far from clear, but an active form of Raf1 was
      and is made at Onyx using a co-infection of Raf1 with
      one or two other oncogenes in a single bacculovirus
      infection, producing a raf1 that can be purified and is
      active. This was used in primary drug screening and a
      compound has come out of this collaberative project that
      is ready for Phase I studies this year. Animal
      models look very good so I hear, and Bayer as well as
      Onyx are not ready to anounce anything formal yet. I
      understand your doubt, but this is what I am hearing from
      multiple an reliable sources.

    • Re:
      :To follow up on the Onyx Christmas party
      anouncement I refered to back on Dec. 22nd: CEO Hollings
      Renton anounced
      that Onyx WILL co-develope the Raf1
      inhibitor drug with Bayer, thereby positioning themselves
      to recieve 50% of the net
      profits on any future
      drug revenue. This further validates the positive
      preliminary results of this drug candidate and shows
      that
      Onyx has not completely lost their collective minds by
      refusing to cash in on the enormous potential of this
      drug
      candidate. The deal allows for most of the money
      that Onyx would put up to co-develope the drug to be
      put up originally by
      Bayer with Onyx repaying the
      debt from future revenue. This is encouraging and
      gives Onyx the potential to be more than
      a one
      product company.
      "

      ..........................

      Have they ever published how they did this? Raf-1 is
      not an easy protein to assay, and the means by which
      they activate it is really key. I would like to know
      more, but initially find this a little
      dubious.

      I'd be happy to be proved wrong.

    • To follow up on the Onyx Christmas party
      anouncement I refered to back on Dec. 22nd: CEO Hollings
      Renton anounced that Onyx WILL co-develope the Raf1
      inhibitor drug with Bayer, thereby positioning themselves
      to recieve 50% of the net profits on any future drug
      revenue. This further validates the positive preliminary
      results of this drug candidate and shows that Onyx has
      not completely lost their collective minds by
      refusing to cash in on the enormous potential of this drug
      candidate. The deal allows for most of the money that Onyx
      would put up to co-develope the drug to be put up
      originally by Bayer with Onyx repaying the debt from future
      revenue. This is encouraging and gives Onyx the potential
      to be more than a one product company.

    • The pen knives given out at the X-mas party
      didn't even have scissors in them I hear! I guess they
      were serious about no bonuses this year! Another
      anouncement more material to the company was made at the
      party; more on that later...

    • The gist of the article appears to be that it's a
      promising treatment, but that the clinical results appear
      to diverge from what the scientists initially
      theorized, giving some doubt as to precisely what is going
      on to cause the anti-tumor activity.

      Here's
      a quote from the article:

      <<But in the
      last few months other researchers have come up with
      contradictory results that "question the reliability of Onyx's
      original preclinical studies," said Dr. Steven P. Linke, a
      molecular biologist at the National Cancer Institute.


      "McCormick has an excellent idea and I hope it
      will work," Dr. Linke said. "But in the new studies,
      the Onyx virus in some cases is unable to kill tumor
      cells that lack p53 function. The conclusion would have
      to be that the killing mechanism is independent of
      p53, although if the clinical trials are successful,
      it may not matter too much how the virus works."
      >>

      The tone of this article is clearly not as bullish as
      was Entremed's good press earlier this year. It good
      press, but not overwhelmingly so, IMHO.

    • New york Times. Today. Science Times. Overview of Onyx's cancer research. It said good things about how the phase two trial is going.

    • Great articles in NY Times Science Section and in SF Examiner on Cancer Research for Onyx. Anybody know anything out there?

    • <<Did anyone see this article/ Is anyone actually discussing onxy here? Very good publicity >>

      What article? What day? What section? What did it say?

    • View More Messages
 
ONXX
124.700.00(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.